key: cord-0964216-g672kz70
authors: Hsieh, Fu-Lien; Chang, Tao-Hsin
title: Antibody Display of cell surface receptor Tetraspanin12 and SARS-CoV-2 spike protein
date: 2021-05-30
journal: bioRxiv
DOI: 10.1101/2021.05.29.446300
sha: b4785fd503321ac8a443f1a2532eddad96b2075c
doc_id: 964216
cord_uid: g672kz70

In previous work, Hsieh and Higgins presented a novel structure of antibodies identified from malaria-exposed individuals, in which the extracellular immunoglobulin (Ig)-like domain of leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is presented on the third complementarity determining regions (CDR3) of the Ig heavy chain. Here we develop an Antibody Display technology based on this LAIR1-containing antibody, by grafting proteins of interest (POI) onto the heavy chain CDR3 while retaining the biological properties of the POI. As a proof of principle, we displayed the second extracellular domain of Tetraspanin12 (Tspan12EC2) and the receptor-binding domain (RBD) of SARS-CoV-2 spike protein on the heavy chain CDR3. Our data revealed that Antibody Display Tspan12EC2 bound to Norrie Disease Protein (Norrin) and Antibody Display SARS-CoV-2 RBD bound to angiotensin-converting enzyme 2 (ACE2) and neutralizing nanobodies. Collectively, Antibody Display technology offers the general strategy of designing novel antibodies by grafting POI onto the CDR3.

In previous work, Hsieh and Higgins presented a novel structure of antibodies identified from 26 malaria-exposed individuals, in which the extracellular immunoglobulin (Ig)-like domain of 27 leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is presented on the third 28 complementarity determining regions (CDR3) of the Ig heavy chain. Here we develop an 29 Antibody Display technology based on this LAIR1-containing antibody, by grafting proteins of 30 interest (POI) onto the heavy chain CDR3 while retaining the biological properties of the POI. 31

As a proof of principle, we displayed the second extracellular domain of Tetraspanin12 32 (Tspan12EC2) and the receptor-binding domain (RBD) of SARS-CoV-2 spike protein on the 33 heavy chain CDR3. Our data revealed that Antibody Display Tspan12EC2 bound to Norrie 34

Result 137

The design of the Antibody Display was informed by structural studies of LAIR1-containing 140 antibody ( Figure 1A ) (Hsieh and Higgins, 2017) . We hypothesized that POI could graft onto the 141 heavy chain CDR3 via two short peptide linkers to generate chimeric antibodies while retaining 142 the biological features of the POI. To test this concept, we focused initially on Tspan12EC2, 143 because (1) Tspan12EC2 protrudes from two transmembrane helices of Tspan12 suggesting that 144 the N-and C-termini of Tspan12EC2 could be linked to b-strands G and F of the heavy chain in a 145 manner that preserves their native spacing ( Figure 1B) and (2) We began our design by searching for homologous structures and conducting a multiple 149 sequence alignment of Tspan25 (CD53) (Yang et al., 2020b) , Tspan28 (CD81) (Kitadokoro et 150 al., 2001; Zimmerman et al., 2016) , and Tspan29 (CD9) (Oosterheert et al., 2020; Umeda et al., 151 2020) with Tspan12, as shown in signal peptide and C-terminal monomeric Venus (mVenus) and 12xHis tags. To assess the level 155 of secreted mVenus fusion protein expression, we used a time-and cost-efficient method, 156 immobilized metal affinity chromatography (IMAC) followed by in-gel fluorescent imaging 157 (Chang et al., 2020) . Variations in the location of the Tspan12EC2 N-and C-termini produced 158 large effects on protein yield (Figure 1-Figure supplement 1C ). Construct 4 (Tspan12 residues 159 116-220) exhibited the highest yield, somewhat less than 0.1 mg/L, consistent with previous 160 studies showing the technical difficulties in producing recombinant Tspan12EC2 (Junge et al., 161 2009; Lai et al., 2017) . As the secretory pathway in mammalian cells has stringent protein 162 quality-control machinery to ensure that secreted proteins are folded correctly (Trombetta and 163 Parodi, 2003) , the expression trials imply that residues 116-220 corresponds to a core folding 164 unit of Tspan12EC2. 165 166 We next generated a three-dimensional model of Tspan12EC2 and designed Antibody Display 167

Tspan12EC2 (Tspan12EC2-AD) model in a Fab format, Fab (Tspan12EC2), by computationally 168 grafting the Tspan12EC2 onto the heavy chain CDR3 based on the structure of LAIR1-containing 169 antibody ( Figure 1C) . We designed constructs based on these principles: (1) placing the core 170 folding unit of Tspan12EC2 at the tip of the heavy chain CDR3 to maximally expose its binding 171 regions for ligand binding, (2) preventing steric clashes between the Tspan12EC2 and the CDR 172 loops of the heavy chain and light chain, and (3) This Tspan12EC2-AD was produced at 1 mg/L, a yield close to that of 182 the LAIR1-containing antibody (Hsieh and Higgins, 2017) , and showed a 10-fold higher 183 expression level than Tspan12EC2 (Figure 1-Figure supplement 1C) . 184 185 Functional analyses of Antibody Display Tspan12EC2 186

Next, to assess if Tspan12EC2-AD adopted the correct fold of Tspan12EC2, we tested the ability of 187 recombinant Tspan12EC2 to bind to Norrin as measured by a colorimetric alkaline phosphatase 188 (AP) reaction-based protein-protein interaction assay using an AP-Norrin fusion protein as a 189 probe (Xu et al., 2004) . Each bait protein had a biotinylated C-terminal Avi-tag and was captured 190 on a streptavidin coated micro-well. Tspan12EC2 bound to AP-Norrin ( Figure 1D and Leucine-rich repeat containing G-protein coupled receptor 4 (Lgr4LRR), extracellular domains 193 that are known to bind to Norrin (Chang et al., 2015; Deng et al., 2013; Shen et al., 2015; Xu et 194 al., 2004) . As expected, AP-Norrin did not bind to Fz5CRD ( Figure 1D ) (Chang et al., 2015; 195 Smallwood et al., 2007) . Importantly, Tspan12EC2-AD bound to AP-Norrin as did Tspan12EC2 196 ( Figure 1D ). Taken together, these results show that (1) EC2 of Tspan12 mediates Norrin 197 binding, in agreement with previous genetic studies using domain swaps within full-length 198

Tspan12 together with co-immunoprecipitation (Lai et al., 2017) , and (2) correctly folded 199

Tspan12EC2 can be grafted onto the heavy chain CDR3 without losing Norrin binding. To assess whether the design principle of the Antibody Display can apply to other protein folds, 203

we tested the RBD of SARS-CoV-2 S protein. We began the design of the Antibody Display 204 SARS-CoV-2 RBD (RBD-AD) by searching the three-dimensional RBD structures of SARS-205

CoV-2 S protein (Barnes et al., 2020; Huo et al., 2020; Lan et al., 2020; Shang et al., 2020; Walls 206 et al., 2020; Wang et al., 2020b; Wrapp et al., 2020b; Yuan et al., 2020; Zhou et al., 2020b) . As 207 shown in Figure 2A , we computationally grafted the RBD structure of SARS-CoV-2 S protein 208 onto the heavy chain CDR3 of LAIR1-containing antibody to generate a model in in a Fab 209 format, Fab (RBD), by using the same design principles as Tspan12EC2-AD. 210 211 Furthermore, we hypothesized that a single VH domain could serve as a scaffold to display 212 SARS-CoV-2 RBD in the absence of light chains. Indeed, human single VH domain mimicking 213 nanobodies from camels has been developed as a minimum size of antigen recognition unit in the 214 absence of light chains (Davies and Riechmann, 1995; Hamers-Casterman et al., 1993) , although 215 specific hallmark mutations are required to maintain the solubility and the binding property of 216 the single VH domain (Davies and Riechmann, 1995; Hamers-Casterman et al., 1993; 217 Muyldermans, 2013) . More recently, Wu et al., identified a highly soluble and stable single VH 218 domain from the human germline Ig heavy chain variable region 3-66*1 (IGHV3-66*1) allele 219 (Wu et al., 2020a) . Therefore, we next designed an engineered single VH domain (eVH) based on 220 the IGHV3-66*1 for the display of SARS-CoV-2 RBD, eVH(RBD), as shown in We present a novel antibody engineering approach, named Antibody Display, by grafting POI 254 onto the heavy chain CDR3, which were designed through a structure-guided approach built on 255 the architecture of LAIR1-containing antibodies naturally occurred in malaria-exposed 256 individuals (Hsieh and Higgins, 2017; Tan et al., 2016) . Most importantly, each POI retained its 257 biological properties by taking advantage of the structural conservation and stability of the 258 antibody Ig fold. As a proof of principle, we showed that the design and production of 259

Tspan12EC2-AD and RBD-AD were successful. Colorimetric AP reaction-based binding assays 260 further revealed that Tspan12EC2-AD bound to Norrin and RBD-AD bound to ACE2 and NBs 261 (VHH-72 and H11-D4). Our findings suggest a generic design principle of the Antibody Display, 262 particularly for the POI adopting a non-Ig like fold: (1) a known structure or a computational 263 model derived from homologous protein structures, (2) N and C termini in proximity to graft 264 onto the b-strands G and F of the heavy chain, and (3) prevention of steric clashes with the 265 antibody. At present, the limitations for selecting POI for Antibody Display such as protein 266 shape and size remain unclear; further studies will be required to address these questions. 267

Comparing with conventional Fc fusion proteins in which the POI is fused to the N terminus of 269 Fc usually including the flexible hinge region, we reasoned that the Antibody Display, which 270 grafts the POI onto the b-strands G and F of the heavy chain, provides several potential 271 advantages: (1) design and production of a more conformationally constrained chimeric protein, 272

(2) reduction of proteolysis with the POI inserted into a stable antibody Ig fold, and (3) extension 273 of the current antibody engineering toolkit for generating bispecific and chimeric antibodies. 274

Further studies will be needed to explore these potential advantages. 275 276 An intriguing feature of using the Antibody Display for Tspan12EC2 is with a better yield of 277 protein production than Tspan12EC2. Our functional assays demonstrated that Tspan12EC2 bound 278 to Norrin directly, in agreement with previous genetic studies (Lai et al., 2017) . As Tspan12 279 playing critical roles in CNS vascular development (Junge et al., 2009; Zhang et al., 2018) and 280 tumorigenesis (Knoblich et al., 2014; Otomo et al., 2014) , Tspan12EC2-AD may be a useful 281 reagent for these studies. Moreover, Tspan proteins are well known for their important roles in 282 regulating tumor migration, invasion and metastasis (Charrin et al., 2014; Hemler, 2014; Vences-283 Catalan and Levy, 2018). Antibodies targeting Tspan29 (CD9), particularly on its EC2 region, 284 have been shown to inhibit the progression of colorectal and gastric cancers (Nakamoto et al., 285 2009; Ovalle et al., 2007) . Furthermore, Tspan proteins are used by several pathogens for 286 infection (Charrin et al., 2014) . For example, Hepatitis C Virus and P. falciparum use Tspan28 287 (CD81) for infection of hepatocytes (Pileri et al., 1998; Silvie et al., 2003) . However, research on 288 Tspan receptors has been hampered by the lack of an efficient approach to produce recombinant 289 EC2 proteins. So far, only Tspan25 (CD53), Tspan28 (CD81), and Tspan29 (CD9) have been 290 produced for biochemical and structural analyses among 33 Tspan receptors (Kitadokoro et al., 291 2001; Oosterheert et al., 2020; Umeda et al., 2020; Yang et al., 2020b; Zimmerman et al., 2016) . 292

More studies will be required to investigate whether the Antibody Display can apply to other 293 Tspan proteins. 294 SARS-CoV-2 has resulted in a global pandemic and several types of COVID-19 vaccines such as 296 nucleic acids, viral vectors, and protein subunits have been developed for vaccinations globally 297 (Connors et al., 2021) . Ongoing studies have shown that the RBD of SARS-CoV-2 S protein is 298 the major target of neutralizing antibodies from COVID-19 convalescent individuals (Barnes et 299 al., 2020; Baum et al., 2020; Brouwer et al., 2020; Chi et al., 2020; Ju et al., 2020; Piccoli et al., 300 2020; Seydoux et al., 2020; Wang et al., 2020a; Wu et al., 2020b) , consistent 301 with recent findings showing that the RBD, particularly decorated on nanoparticles, can induce a 302 protective humoral immune response against SARS-CoV-2 infection (Cohen et al., 2021; Tan et 303 al., 2021; Yang et al., 2020a) . In this report, we demonstrated that the Antibody Display can be 304 used to display the RBD of SARS-CoV-2 S protein on the heavy chain CDR3 without losing its 305 binding properties. It is not yet known whether RBD-AD can induce neutralizing antibodies, but 306 it would be an interesting test case and it could be relevant for the future preparedness and 307 response capacity against emerging SARS-CoV-2 variants. 308 The pHLsec-Fc-Avi-6H vector contains the human immunoglobulin heavy constant gamma 1 336 (resi 101-330; UniProtKB code P01857) followed by an Avi tag that can be biotinylated by BirA 337 ligases and a 6xHis tag. (3) The pHLsec-3C-mVenus-Avi-8H vector derived from pHLsec-338 mVenus-12H (Chang et al., 2015) was tagged with a C-terminally HRV-3C protease cleavage 339 site followed by a mVenus fusion protein, an Avi tag and finally an 8xHis tag. (4) The pHL-N-340 AP-Myc-8H vector was constructed N-terminally with the human alkaline phosphatase (AP; resi 341 1-506; NCBI code NP_001623) followed by a Myc tag and finally a C-terminal 8xHis tag. (5) 342 The pHLsec-C-Myc-AP-8H vector contains a C-terminal Myc tag followed by the human AP 343 (resi 18-506; NCBI code NP_001623) and finally an 8xHis tag. 344 345 Tspan12 coding segments for the EC2 were PCR-amplified and cloned into the pHLsec-346 mVenus-12H (Chang et al., 2020; Chang et al., 2015) . Tspan12EC2 inserts were grafted into a 347 modified MGD21 heavy chain vector containing a C-terminal HRV-3C protease cleavage site 348 followed by a mVenus fusion protein and finally an 8xHis tag (pHLsec-mMGD21-3C-mVenus-349

Avi-8H), by using three-fragments overlapping PCR experiments. The MGD21 light chain 350 mutant (C91A and C93A) vector was generated by using a two-step overlapping PCR method. (Aricescu et 377 al., 2006; Chang et al., 2015; Hsieh and Higgins, 2017; Hsieh et al., 2016) . For Antibody Display 378

Tspan12EC2, DNA constructs expressing heavy chain and light chain were mixed into a 1 to 1 379 ratio and co-expressed in HEK293T cells. For the biotinylated bait preparations, bait constructs 380 were mixed with a pHLsec-BirA-ER vector (Chang et al., 2015) into a 3 to 1 ratio and co-381 transfected in HEK293T cells in the presence of 0.1 mM Biotin (MilliporeSigma B4639). The 382 biotinylated baits were purified from conditioned media by the immobilized metal affinity 383 chromatography (IMAC) method as previously described in (Chang et al., 2020) . IMAC method 384 was also used for the purification of His tagged Fc fusion and AP fusion proteins. To evaluate 385 the expression level of secreted mVenus fusion proteins from conditioned media, IMAC 386 followed by an in-gel fluorescence imaging method was used as previously described in (Chang 387 et al., 2020) . The RBD (magenta) of SARS-CoV-2 S protein is displayed on the VH (yellow). A schematic diagram shows the binding sites on the RBD for ACE2ECD (green), NBVHH-72 (orange), and NBH11-D4 (grey). (B) A diagram of the RBD of SARS-CoV-2 S protein is displayed on the engineered VH fused to a mVenus, an Avi tag, and an 8xH tag at the Cterminus. For the AP based binding assay, biotinylated baits were immobilized on streptavidincoated wells. Bound AP fusion proteins (probes) were visualized with BluePhos phosphatase substrate solution. BSA and Fz5CRD fusion proteins are used as negative controls. (C) Diagram of SARS-CoV-2 RBD-containing engineered VH fused an 8xH tagged human Fc. FC baits were captured on protein-G coated wells and incubated with AP fusion proteins (probes). The bait and probe interactions were detected as in panel (B). Multiple sequence alignment of Tspan12EC2 with current available Tspan structures including Tspan25 (CD53; PDB code 6WVG), Tspan28 (CD81, PDB codes 1G8Q and 5TCX), and Tspan29 (CD9, PDB codes 6RLR and 6K4J). Identical residues are shaded in dark and similar residues in grey. Secondary structure elements (five α-helical regions A to E) are indicated based on the structures of Tspan25, Tspan28, and Tspan29. The conserved cysteine residues are highlighted in cyan. Tspan12 has two additional cysteine residues (a red box) conserved in the vertebrate. (B) Eight Tspan12EC2 expression constructs were cloned in the pHLsec-mVenus-12H vector. (C) Tspan12EC2 constructs having the mVenus fusion were transfected in HEK293T cells. Fz4CRD with the mVenus fusion was used to compare the expression level. The conditioned media (1 ml) were purified by immobilized metal affinity chromatography (IMAC) and protein expression levels were determined by in-gel fluorescence imaging and Coomassie blue staining (Chang et al., 2020) . Figure 1B for a brief schematic representation of construct design. (A) Five inserts containing various fragments of Tspan12EC2 and connecting linker sequences were cloned into a modified antibody MGD21 heavy chain vector containing a HRV 3C protease cleavage site followed by a mVenus and an 8xHis tag. Constructs 1 to 4 were co-expressed with the MGD21 light chain vector in HEK293T cells. Construct 5 which lacks residue C223 on the VH was co- The amino acid sequence of the RBD of SARS-CoV-2 S protein displayed on the engineered VH. Engineered VH is a chimeric fusion of the VH region of IGHV3-66*1 highlighted in cyan (the C73S mutation is used to prevent the formation of artificial disulphide bonds and is boxed in blue) and a part of MGD21 VH region highlighted in yellow (the N242S mutation is used to block the N-linked glycosylation and is boxed in purple; two residues, Y235 and Y236, are removed from the sequence by complementing the insertion of an AscI restriction site). The RBD (highlighted in magenta) of SARS-CoV-2 S protein contains a P527A mutation (boxed in white) by enhancing model restraint for the insertion. Red boxes denote two conserved cysteine residues of VH forming a disulphide bond. A green box indicates an N-linked glycosylation site of the RBD of SARS-CoV-2 S protein. The in-gel fluorescence imaging shows the biotinylated Fab (RBD)-mVenus-Avi-8H bait that was purified by IMAC from the conditioned media and used for the binding assay. (B) Biotinylated Fab (RBD) baits were immobilized on streptavidin-coated wells. Bound AP fusion probes were visualized by a colorimetric AP reaction (blue).

A time-and cost-efficient system for high-level protein production in mammalian cells

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Structure of the RECK CC domain, an evolutionary anomaly

Structure and functional properties of Norrin mimic Wnt for signalling with Frizzled4, Lrp5/6, and proteoglycan

Tetraspanins at a glance

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Conformations of immunoglobulin hypervariable regions

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn

Antibody VH domains as small recognition units

Multifunctional norrin is a ligand for the LGR4 receptor

Human Coronavirus: Host-Pathogen Interaction

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Cooperative role for tetraspanins in adhesin-mediated attachment of bacterial species to human epithelial cells

Naturally occurring antibodies devoid of light chains

Tetraspanin proteins promote multiple cancer stages

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The structure of a LAIR1-containing human antibody reveals a novel mechanism of antigen recognition

The structural basis for CD36 binding by the malaria parasite

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Human neutralizing antibodies elicited by SARS-CoV-2 infection

TSPAN12 regulates retinal vascular development by promoting Norrin-but not Wnt-induced FZD4/beta-catenin signaling

Structure and function of Norrin in assembly and activation of a Frizzled 4-Lrp5/6 complex

CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs

Tetraspanin TSPAN12 regulates tumor growth and metastasis and inhibits beta-catenin degradation

TSPAN12 Is a Norrin Co-receptor that Amplifies Frizzled4 Ligand Selectivity and Signaling

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Role of the Norrie disease pseudoglioma gene in sprouting angiogenesis during development of the retinal vasculature

Nanobodies: natural single-domain antibodies

A novel therapeutic strategy with anti-CD9 antibody in gastric cancers

Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy

Implications for tetraspanin-enriched microdomain assembly based on structures of CD9 with EWI-F

TSPAN12 is a critical factor for cancerfibroblast cell contact-mediated cancer invasion

The tetraspanin CD9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells

Kuby immunology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Public antibodies to malaria antigens generated by two LAIR1 insertion modalities

Binding of hepatitis C virus to CD81

Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy

Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81

Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Structural basis of receptor recognition by SARS-CoV-2

Structural basis of the Norrin-Frizzled 4 interaction

Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity

Mutational analysis of Norrin-Frizzled4 recognition

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature

A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q

Quality control and protein folding in the secretory pathway

Immune Targeting of Tetraspanins Involved in Cell Invasion and Metastasis. Front Immunol 9

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A human monoclonal antibody blocking SARS-CoV-2 infection

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Interplay of the Norrin and Wnt7a/Wnt7b signaling systems in blood-brain barrier and blood-retina barrier development and maintenance

Site-specific glycan analysis of the SARS-CoV-2 spike

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Identification of Human Single-Domain Antibodies against SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

Open conformation of tetraspanins shapes interaction partner networks on cell membranes

Molecular Architecture of the SARS-CoV-2 Virus

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Endothelial Cell-Specific Inactivation of TSPAN12 (Tetraspanin 12) Reveals Pathological Consequences of Barrier Defects in an Otherwise Intact Vasculature

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains

Residues SFQ (173-175) in the large extracellular loop of CD9 are required for gamete fusion

A Novel Coronavirus from Patients with Pneumonia in China

transfected in HEK293T cells with an MGD21 light chain vector containing double mutations C91A and C93A (C93A mutation was used to block an inter-chain disulphide formation by VH C223 and VL C93

Green hexagons denote N-linked glycosylation sites. Black triangles show VH C223. Star indicates VL C91. (B) The conditioned media were harvested 2 days post-transfection and purified by IMAC